معرفی
Dr. Jarno Hoekman is an Associate Professor in Innovation Studies at the Copernicus Institute of Sustainable Development, Utrecht University. His research focuses on the dynamics and governance of science in the context of innovation, regulation, and societal challenges, with particular emphasis on sustainability and health. He is affiliated with both the Copernicus Institute of Sustainable Development and the Utrecht collaborating Centre for Pharmaceutical Policy & Regulation in the Department of Pharmaceutical Sciences. Dr. Hoekman serves as the programme leader of the research master in Innovation Sciences and teaches academic integrity courses to Master students and PhD candidates.
Dr. Hoekman's research is organized around three interconnected themes: Science in transition, examining how scientific practices and institutional arrangements are evolving through open science, interdisciplinary research collaborations, and alternative recognition systems; Regulatory science and innovation, investigating innovations in tools and standards for assessing risks and benefits of new technologies, including safety assessment methods and regulatory authorization standards; and Geography of science, exploring the role of location factors in scientific knowledge production and diffusion.
Analysis of Dr. Hoekman's recent publications (2022-2024) reveals a strong interdisciplinary focus spanning pharmacology, toxicology, innovation studies, and science policy. Key research trends include examining conditional marketing authorization pathways, post-approval studies for conditionally authorized medicines, animal-free safety testing methodologies, and the societal impact of transdisciplinary research projects. His work frequently employs mixed-methods approaches and involves multi-stakeholder perspectives to address complex regulatory and innovation challenges.
Dr. Hoekman actively contributes to policy-relevant research, including major European Commission studies on pharmaceutical legislation. His collaborative work extends across multiple institutions and involves interdisciplinary teams working on pharmaceutical policy, sustainable innovation, and science-society interactions. As a member of the Utrecht Young Academy and the UU Open Science Platform, he engages with broader academic community initiatives related to research integrity and open science practices.
